Insider Cluster (2 insiders) ·Filed Mar 13, 2026

CNTA

Centessa Pharmaceuticals plc
BEARISH
Impact 6/10
Horizondays Processed6mo ago
Insider cluster: 2 insiders, $4.4M total
Actionable Insight ▼ Bearish

Traders should monitor for potential downward pressure on CNTA shares, especially if this selling follows weak clinical data, lack of near-term catalysts, or broader biotech sector weakness. Assess whether this is part of a routine post-vesting disposition or a signal of deteriorating confidence.

DirectionBearish
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
CNTA ▲ +50.78% at T+60d
SHORT call ✗ call lost -50.78% · α vs SPY -39.16% · entry $26.33 → $39.70
Entry anchored
Mar 12, 03:59 PM ET
via exchange tick
T+1d
+7.44%
call -7.44% · α -6.42%
$28.29
settled 7mo ago
T+5d
+2.77%
call -2.77% · α -4.89%
$27.06
settled 7mo ago
T+20d
+50.28%
call -50.28% · α -46.70%
$39.57
settled 6mo ago
T+60d
+50.78%
call -50.78% · α -39.16%
$39.70
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

Centessa Pharmaceuticals insiders executed a significant share disposition cluster within one day, led by the Chief People Officer selling $2.82M in shares and exercising derivatives, alongside the Chief Business Officer selling $1.6M. The total open-market sales amount to $4.43M, representing a notable insider selling event.

Key Financial Metrics

Direction
selling
Total Value
$4.4M
Insiders
2

Key Facts

  • Chief People Officer Karen M. Anderson sold 107,961 shares for $2,823,234 in open-market transactions.
  • Anderson also exercised derivative securities involving 218,796 shares with a total cost basis of $438,686, resulting in no cash inflow for the company.
  • Chief Business Officer Gregory M. Weinhoff sold 61,253 shares for $1,602,795 in open-market transactions.
  • Total open-market proceeds from insider sales: $4,426,029 over a single day.

Financial Impact

$4.43M in open-market insider sales over one day, representing ~0.11% of Centessa's $3.9B market cap

insider ownershipinvestor sentimentshare supply

Risk Factors

  • Insider selling may signal lack of confidence in near-term prospects, particularly from C-suite executives.
  • Risk of negative market perception amplifying selling pressure, especially in a volatile biotech environment.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CONTEXT: Insider Cluster Data (4 trades, 7d window)cluster-CNTA-1773440631845
5 reports for CNTA
Performance horizon
67% Hit rate 2 of 3 directional calls best @ T+20▲ +0.33%Apr 17, 2026
Filters
Rows
Reports for CNTA — sortable, filterable
TypeNow
Jul 6, 2026
12w ago
15-12G
BEARISH ★ 7/10
—awaiting T+20——
Apr 17, 2026
23w ago
PREM14A
BULLISH ★ 9/10
$39.51 $39.64▲ +0.33%▼ −3.87%—
Apr 13, 2026
24w ago
DEFA14A
BULLISH ★ 8/10
$39.59 $39.59· 0.00%▼ −6.30%—
Mar 13, 2026
29w ago
Insider Cluster
BEARISH ★ 7/10
$26.33 $39.57▼ −50.28%▼ −46.70%—
Mar 13, 2026
29w ago
Insider Cluster
BEARISH ★ 6/10
$26.33 $39.57▼ −50.28%▼ −46.70%—
Showing 5 of 5

US Market Status

Market Open — Closes in 4h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Mar 13, 2026